Physician profile
Su-Yong Pak
NPI 1437169372
$1,958.54
in general payments reported to CMS, 2019-2025
18 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $29.32 · 2021: $79.55 · 2022: $12.84 · 2023: $175 · 2024: $264 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $349.75 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $255.77 | 2019-2024 | Airsupra, Farxiga |
| Aimmune Therapeutics, INC. | $210.45 | 2024-2025 | Zenpep |
| Amgen INC. | $207.07 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $149.04 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $124.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.35 | 2019 | |
| Neurocrine Biosciences, INC. | $115.98 | 2023 | Ingrezza |
| Medtronic Vascular, INC. | $103.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $101.10 | 2019 | |
| Novo Nordisk INC | $65.62 | 2022-2024 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $32.23 | 2025 | |
| Esperion Therapeutics, INC. | $26.57 | 2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $23.89 | 2025 | Rexulti |
| Lilly USA, LLC | $22.08 | 2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.11 | 2023 | Rexulti |
| Allergan, INC. | $15.98 | 2019 | |
| Astellas Pharma US INC | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su-Yong Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.